Genetically engineered mouse models are an indispensable tool for studying human development and disease, enabling us to characterize gene functions in vivo, to investigate the cellular and molecular mechanisms of physiological and pathological processes, and to establish faithful disease models for drug screen. To date, most mouse models are engineered to recapitulate human disease phenotype, yet more sophisticated mouse models are in demand to study disease gene function in a native cellular background, to perform single cell based analyses and to set up high-throughput reporter-based screens for phenotypes or therapy. Fluorescent tagging of endogenous genes is a particularly powerful strategy, allowing the characterization of subcellular localization of proteins, identification of interaction partners, and isolation of specific cell populations in the context of development and disease. Engineering functional tags in an endogenous gene locus of interest preserves endogenous expression and minimizing genomic disruption, but the technology still remains inefficient, costly and laborious. We recently developed CRISRP-EZ (CRISPR RNP Electroporation of Zygotes), an electroporation-based technology that outperforms microinjection in efficiency, simplicity, cost, and throughput for mouse genome editing. Based on the CRISPR-EZ technology, we aim to develop novel technologies to achieve rapid fluorescent tagging of endogenous proteins with unprecedented efficiency, simplicity, throughput and cost saving. First, we will employ the self- complementing split-GFP system to achieve functional GFP tagging of endogenous genes in vivo using CRISPR-EZ. Second, we will develop CRISPR-READI (CRISPR RNP Electroporation and AAV Donor Infection) to engineer full length fluorescent protein tagging on endogenous loci in mice by AAV-mediated HDR editing. Taken together, our technologies will allow efficient and high throughput fluorescent tagging in mouse disease models for comprehensive mechanistic studies and powerful drug screening.

Public Health Relevance

Our preliminary studies developed CRISRP-EZ (CRISPR RNP Electroporation of Zygotes), an electroporation-based technology that outperforms the classic microinjection method for mouse genome engineering with simple editing schemes. Using CRISPR-EZ, the split GFP system, and AAV mediated HDR editing, we aim to develop novel methodologies for highly efficient, high throughput and economic fluorescent tagging of endogenous disease-related genes. Our technologies will greatly enhance our capacity to build better mouse disease models for functional characterization, mechanistic studies and reporter-based high throughput phenotype/drug screens.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21OD027053-02
Application #
9993600
Study Section
Therapeutic Approaches to Genetic Diseases Study Section (TAG)
Program Officer
Zou, Sige
Project Start
2019-08-15
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
2
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Berkeley
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94710